

PROJECT REPORT
Of
FINXORA DIAGNOSTICS LLP

GST No.: 23AAABF0000A1Z5
UDYAM No.: UDYAM-MP-00-0000000

For Term Loan of 1,18,80,000.00 /- and CC of 12,40,000.00 /-



INDEX

Description	Page No.
COMPANY PROFILE	3
RATIO ANALYSIS	5
DSCR	8
TURNOVER METHOD OF LENDING	9
MAXIMUM PERMISSIBLE BANK FINANCE (MPBF)	10
PROJECT NARRATIVE	11
SALES & PURCHASE BREAKDOWN	16
REVENUE & EXPENSES	19
PROJECT COST BREAKDOWN	20
MEANS OF FINANCE	20
PROFIT & LOSS ACCOUNT	21
CASH FLOW STATEMENT	22
BALANCE SHEET	23
DEPRECIATION	24
BREAKEVEN POINT	26
EMI REPAYMENT SCHEDULE	27
EXPLANATIONS & CONCLUSION	29

COMPANY PROFILE

I. Company Information

Name of the Company/Firm	FINXORA DIAGNOSTICS LLP
Partner 1	Aarav Mehta (Male, General)
Partner 2	Neha Kapoor (Female, General)
Constitution	llp
Address	Plot 12, Industrial Area, Indore, Madhya Pradesh 452001
PAN No.	AAABF0000A
Date of Incorporation/Birth	01-Apr-2026
Industry	Pathology laboratory service
Type of Business	service
Business Starting Date	01-Apr-2026
Type of Loan	TERM-LOAN Loan
Father/Spouse/Guardian Name	Dev Mehta
Marital Status	Married
Educational Qualification	Graduate with sector training
Profession/Occupation	Pathology laboratory service
Contact Number	0000000000
Email	sample@finxora.com
Aadhaar No.	0000 0000 0000
Business description	Pathology laboratory service serving institutional and retail customers in Indore and neighbouring districts of Madhya Pradesh. Operations combine documented customer orders, supplier evaluation, quality checks and regular collection follow-up. Management reviews stock, receivables and cash flow monthly to maintain service standards and timely debt repayment.
Incorporation / establishment	01-Apr-2026
Bank and branch	XYZ Bank Ltd., Indore Main Branch
Proposed facilities	Cash credit Rs. 12.4 lakh and term loan Rs. 118.8 lakh
Ownership / management	Aarav Mehta: 50% (designated partner); Neha Kapoor: 50% (designated partner)
Market and operations	Diversified local customers; documented orders; monthly stock and debtor review.

II. Project & Financial Overview

Report Period	2026 - 2030
Currency	INR
Amount In	Actual
Total Project Cost	INR 2,32,40,000.00
Term Loan Bank	XYZ Bank Ltd.
Term Loan	INR 1,18,80,000.00
Term Loan Duration	5 years
Term Loan Interest Rate (%)	9.5%
Term Loan Installment (monthly)	INR 2,71,221.99
Repayment Frequency	Monthly
WC (CC/OD) Bank	XYZ Bank Ltd.
Working Capital Loan	INR 12,40,000.00
WC Loan Interest Rate (%)	10%
Own Contribution	INR 1,01,20,000.00

III. Financial Indicators

Particulars	Value
Average DSCR	2.90
Average Current Ratio	2.29
Debt-Equity Ratio (Year 1)	0.77
Break-Even Point % (Year 1)	55.35%

Ratio Analysis

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Liquidity Ratios					
Current Ratio	1.35	1.77	2.10	2.35	3.88
Quick Ratio (Acid Test)	1.24	1.66	2.00	2.24	3.73
Profitability Ratios					
Gross Profit Ratio (%)	43.70	43.70	43.70	43.70	43.70
Net Profit Ratio (%)	13.42	15.18	16.72	17.59	18.12
EBDIT Margin (%)	32.00	32.00	32.00	32.00	32.00
Return on Capital Employed (%)	19.36	22.83	25.84	27.71	25.67
Return on Equity (%)	32.45	31.51	30.14	28.02	25.91
Leverage Ratios					
Debt-Equity Ratio	0.77	0.46	0.23	0.06	0.05
Debt to Total Assets (%)	35.97	25.41	14.82	4.54	4.20
Interest Coverage Ratio (Times)	5.91	8.04	11.73	19.12	42.14
Debt Service Coverage Ratio (DSCR)	3.61	2.56	2.69	2.79	2.87
Solvency Ratios					
Proprietary Ratio	0.47	0.56	0.65	0.74	0.82
Solvency Ratio (%)	1.11	1.30	1.55	1.85	2.49
TOL / TNW Ratio	1.15	0.80	0.54	0.36	0.22
Fixed Asset Coverage Ratio	2.23	2.79	4.53	49.87	44.42
Debt / EBITDA (x)	1.00	0.69	0.40	0.12	0.11
Contribution Ratio (%)	43.55	43.55	43.55	43.55	43.55


Liquidity Ratios



Analysis:

Liquidity ratios monitor the firm's ability to settle short-term liabilities. The Current Ratio, starting at 1.35:1 and reaching 3.88:1 by the final year, indicates a healthy buffer of current assets. The Quick Ratio follows a similar positive trend, ensuring that the firm can meet its obligations even without relying on inventory liquidation.

Profitability Ratios



Analysis:

Profitability ratios reflect the operational efficiency of the project. The Gross Profit margin begins at 43.70%, while the Net Profit margin starts at 13.42%. The consistency or growth in these margins over the years demonstrates the firm's capability to manage costs and generate returns for the stakeholders.


Solvency Ratios



Analysis:

Solvency ratios provide a long-term perspective on the firm's health. They indicate the project's ability to sustain operations and meet long-term commitments, ensuring viability beyond the initial projection period.


Leverage Ratios



Analysis:

Leverage ratios evaluate the project's capital structure and dependence on debt. The Debt-Equity ratio of 0.77:1 in the initial year shows the balance between borrowed funds and owner's equity. A stable or decreasing ratio over time typically indicates a lower risk profile and greater financial independence.

Working Capital Turnover



Analysis:

Efficiency ratios (Turnover Ratios) indicate how effectively the firm is utilizing its assets. High turnover figures suggest optimal inventory management and efficient use of working capital, resulting in better overall productivity.

Efficiency Ratios




Analysis:

Efficiency ratios (Turnover Ratios) indicate how effectively the firm is utilizing its assets. High turnover figures suggest optimal inventory management and efficient use of working capital, resulting in better overall productivity.

DSCR

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Receipts					
a).Net Profit	41,61,479.86	50,82,030.98	60,45,271.91	68,70,620.41	76,40,164.18
b).Depreciation	26,40,000.00	22,77,000.00	19,65,150.00	16,97,107.51	14,66,598.37
c).Interest on termloan	11,07,337.42	9,25,927.08	6,94,805.58	4,40,745.84	1,61,471.27
Total	79,08,817.28	82,84,958.06	87,05,227.49	90,08,473.76	92,68,233.82
Repayments					
a).Loan Principal	10,84,294.49	23,10,445.71	25,39,751.87	27,91,816.11	30,68,897.11
b).Interest on termloan	11,07,337.42	9,25,927.08	6,94,805.58	4,40,745.84	1,61,471.27
Total	21,91,631.91	32,36,372.79	32,34,557.45	32,32,561.95	32,30,368.38
DSCR	3.61	2.56	2.69	2.79	2.87
Average DSCR					2.90


Dscr



Analysis:

The Debt Service Coverage Ratio (DSCR) is a primary indicator of debt-repayment capacity. With an average DSCR of 2.90 over the 5-year period, the project demonstrates a strong ability to generate sufficient cash flows to meet both interest and principal obligations comfortably.

Balance Sheet Strength



Analysis:

The Balance Sheet Strength chart illustrates the growth of Total Assets and Tangible Net Worth (TNW) over the projection period. In FY 2026-27, Total Assets are projected at 2,75,47,900.52 alongside a Tangible Net Worth of 1,28,24,961.91. By FY 2030-31, these are expected to reach 3,59,40,352.84 and 2,94,89,718.78 respectively. This trend signifies a strengthening financial position and increasing equity cushion for the firm.

Turnover Method of Lending

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
A. Turnover (Net Sales)	3,10,00,000.00	3,34,80,000.00	3,61,58,400.00	3,90,51,072.00	4,21,75,157.76
B. 25.00% of (A)	77,50,000.00	83,70,000.00	90,39,600.00	97,62,768.00	1,05,43,789.44
C. Margin Required at 5.00% of (A)	15,50,000.00	16,74,000.00	18,07,920.00	19,52,553.60	21,08,757.89
D. Margin (NWC)	21,34,518.67	51,75,086.94	82,77,847.57	1,13,71,961.23	1,78,04,666.30
E. (B - C)	62,00,000.00	66,96,000.00	72,31,680.00	78,10,214.40	84,35,031.55
F. (B - D)	56,15,481.33	31,94,913.06	7,61,752.43	-16,09,193.23	-72,60,876.86
G. Permissible Bank Finance under Turnover Method (B - C)	62,00,000.00	66,96,000.00	72,31,680.00	78,10,214.40	84,35,031.55
H. Proposed / Existing Bank Borrowing	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
I. Drawing Power	15,73,776.18	14,33,193.67	12,95,401.96	9,95,942.18	6,04,779.72
J. Excess Borrowing over Turnover Method Finance	0.00	0.00	0.00	0.00	0.00

Maximum Permissible Bank Finance (MPBF)

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
FIRST METHOD OF LENDING					
1. Total Current Assets	81,87,900.52	1,19,24,494.46	1,57,69,338.98	1,98,20,399.60	2,39,86,208.70
2. Other Current Liabilities (Other than Bank Borrowing)	48,13,381.85	55,09,407.52	62,51,491.41	72,08,438.37	49,41,542.40
3. Working Capital Gap	33,74,518.67	64,15,086.94	95,17,847.57	1,26,11,961.23	1,90,44,666.30
4. Min stipulated Net Working Capital (25% of Working Capital Gap)	8,43,629.67	16,03,771.74	23,79,461.89	31,52,990.31	47,61,166.57
5. Actual / Projected Net Working Capital	21,34,518.67	51,75,086.94	82,77,847.57	1,13,71,961.23	1,78,04,666.30
6. Item 3 minus item 4	25,30,889.00	48,11,315.21	71,38,385.68	94,58,970.92	1,42,83,499.72
7. Item 3 minus item 5	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
8. Maximum Permissible Bank Finance (lower of 6 or 7)	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
9. Excess Borrowing Representing shortfall in NWC	0.00	0.00	0.00	0.00	0.00
SECOND METHOD OF LENDING					
1. Total Current Assets	81,87,900.52	1,19,24,494.46	1,57,69,338.98	1,98,20,399.60	2,39,86,208.70
2. Other Current Liabilities (Other than Bank Borrowing)	48,13,381.85	55,09,407.52	62,51,491.41	72,08,438.37	49,41,542.40
3. Working Capital Gap	33,74,518.67	64,15,086.94	95,17,847.57	1,26,11,961.23	1,90,44,666.30
4. Min stipulated Net Working Capital (25% of Total Current Assets)	20,46,975.13	29,81,123.62	39,42,334.75	49,55,099.90	59,96,552.17
5. Actual / Projected Net Working Capital	21,34,518.67	51,75,086.94	82,77,847.57	1,13,71,961.23	1,78,04,666.30
6. Item 3 minus item 4	13,27,543.54	34,33,963.33	55,75,512.83	76,56,861.33	1,30,48,114.12
7. Item 3 minus item 5	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
8. Maximum Permissible Bank Finance (lower of 6 or 7)	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
9. Excess Borrowing Representing shortfall in NWC	0.00	0.00	0.00	0.00	0.00

Executive Summary

FINXORA DIAGNOSTICS LLP proposes to establish a pathology laboratory service business in Indore, Madhya Pradesh. Commercial commencement is planned for 1 April 2026, with the investment and funding structure set out in the project schedules. The laboratory will provide routine pathology panels and specialised diagnostic panels. The revenue plan allocates 60% of sales to routine panels at Rs. 500 per test and 40% to specialised panels at Rs. 1,200 per test. Reagents and approved outsourced work are linked to these service lines, allowing management to monitor contribution by panel rather than rely only on aggregate billings.

Demand for accessible local diagnostics supports a laboratory offering dependable turnaround and traceable results. Clinics and employers may provide recurring work, while walk-in patients diversify collections. Management will build referral relationships around quality and service consistency, with specialised panels introduced only where equipment capability and expected throughput justify the reagent and quality-control costs.

The funding schedule provides a total outlay of Rs. 232.40 lakh, promoter contribution of Rs. 101.20 lakh, term finance of Rs. 118.80 lakh and cash credit of Rs. 12.40 lakh. The term facility is modelled at 9.5% over five years with a six-month moratorium; working-capital interest is modelled at 10%. Security documentation and final repayment terms remain subject to the bank's appraisal and sanction. For the first reporting year, FY 2026-27, the computed schedules show sales of Rs. 310.00 lakh and net profit of Rs. 41.61 lakh. The first-year current ratio is 1.70 times and the arithmetic average of the annual DSCR values in the repayment schedule is 2.90 times. Final-year sales are Rs. 421.75 lakh with net profit of Rs. 76.40 lakh; these highlights reproduce the report's calculations rather than a separate earnings estimate.

Company Background

Aarav Mehta brings twelve years of diagnostic laboratory operations and sample-processing experience. Neha Kapoor has ten years of healthcare administration and financial management experience. The designated partners contribute equally and will appoint a suitably qualified laboratory head for technical supervision; clinical authorisation and quality oversight remain with appropriately qualified professionals.

The staffing plan includes eight laboratory and collection personnel, three reception and billing staff and two administrative staff, with professional technical supervision. Equipment installation, calibration, staff training and applicable registrations are to precede commencement on 1 April 2026. Biomedical-waste arrangements and backup power must be in place before patient samples are accepted. Responsibilities should be supported by written authority limits for purchases, customer credit and payments. Bank reconciliations and statutory compliance are to be reviewed monthly, and changes in key personnel should be accompanied by a documented handover.

Daily internal controls, calibration records and external proficiency review are central to reliable results. Samples failing identification or collection requirements are rejected through a documented procedure. Report access is restricted to authorised staff, and corrected results retain an audit trail; maintenance and reagent storage conditions are reviewed with the

laboratory head. The reporting plan calls for consistent accounting policies, periodic physical verification and management review of exceptions. Forecast growth is an operating target and should be measured against demonstrated execution rather than treated as an assured result.

Project Scope and Implementation

The premises at Plot 12, Industrial Area, Indore are planned with separate reception, sample collection, processing and controlled storage areas. Equipment and collection staffing are designed for up to 250 routine-equivalent tests per working day, allowing headroom over the initial volume plan. Sample identification, transport conditions and turnaround times are logged from receipt to authorised report release.

The staffing plan includes eight laboratory and collection personnel, three reception and billing staff and two administrative staff, with professional technical supervision. Equipment installation, calibration, staff training and applicable registrations are to precede commencement on 1 April 2026. Biomedical-waste arrangements and backup power must be in place before patient samples are accepted.

Implementation should proceed through premises readiness, equipment procurement, installation, trial operation and controlled commercial launch. Supplier specifications and service support should be checked before placing orders. Promoter margin is to be introduced in step with disbursement; the bank should verify end use against invoices and the agreed project budget. Any commissioning delay requires a revised sales ramp and repayment forecast before full utilisation of the facilities.

Operational Plan

The premises at Plot 12, Industrial Area, Indore are planned with separate reception, sample collection, processing and controlled storage areas. Equipment and collection staffing are designed for up to 250 routine-equivalent tests per working day, allowing headroom over the initial volume plan. Sample identification, transport conditions and turnaround times are logged from receipt to authorised report release.

The staffing plan includes eight laboratory and collection personnel, three reception and billing staff and two administrative staff, with professional technical supervision. Equipment installation, calibration, staff training and applicable registrations are to precede commencement on 1 April 2026. Biomedical-waste arrangements and backup power must be in place before patient samples are accepted.

The laboratory will provide routine pathology panels and specialised diagnostic panels. The revenue plan allocates 60% of sales to routine panels at Rs. 500 per test and 40% to specialised panels at Rs. 1,200 per test. Reagents and approved outsourced work are linked to these service lines, allowing management to monitor contribution by panel rather than rely only on aggregate billings. Monthly management review should compare orders, realised prices, direct costs and collections with the financial schedules. Stock and debtor statements must reconcile with the books before submission to the bank. Any adverse movement in margin or overdue

accounts should lead to a revised cash-flow forecast and corrective action before additional credit commitments are accepted.

Market Analysis and Opportunity

The proposed customer groups include local patients, medical practitioners, clinics and employers arranging health checks. Referrals are developed through service reliability and transparent reporting timelines, with patient consent and privacy incorporated into the collection process. Corporate accounts are assessed for credit terms separately from patients who ordinarily settle at the time of service.

Demand for accessible local diagnostics supports a laboratory offering dependable turnaround and traceable results. Clinics and employers may provide recurring work, while walk-in patients diversify collections. Management will build referral relationships around quality and service consistency, with specialised panels introduced only where equipment capability and expected throughput justify the reagent and quality-control costs.

The forecast assumes disciplined expansion of existing product and service lines, supported by the annual growth and collection assumptions in the schedules. Local competition, customer bargaining power and input-cost changes require regular review of quotations. Before expanding into another territory or customer group, management should compare incremental gross contribution with delivery, staffing and credit costs and retain only business that supports the repayment plan.

Quality Assurance and Control

Daily internal controls, calibration records and external proficiency review are central to reliable results. Samples failing identification or collection requirements are rejected through a documented procedure. Report access is restricted to authorised staff, and corrected results retain an audit trail; maintenance and reagent storage conditions are reviewed with the laboratory head.

The premises at Plot 12, Industrial Area, Indore are planned with separate reception, sample collection, processing and controlled storage areas. Equipment and collection staffing are designed for up to 250 routine-equivalent tests per working day, allowing headroom over the initial volume plan. Sample identification, transport conditions and turnaround times are logged from receipt to authorised report release. Operating records should link purchases or inputs to completed output and customer billing, allowing exceptions to be traced promptly. Responsibility for acceptance checks, stock custody and payment approval should be separated wherever staffing permits.

Management should retain supplier documents, maintenance records, customer complaints and corrective-action logs. Quality controls are intended to prevent avoidable returns and interruption as well as meet customer specifications. Periodic review of losses, rework and complaints should feed into costing and training; certifications or approvals should be claimed only after the applicable requirements have been met.

Risk Assessment and Mitigation

A slower referral build-up, equipment failure and errors in sample handling can affect both revenue and reputation. Phased marketing, preventive maintenance and approved referral-laboratory backup reduce interruption risk. Staff competency checks, internal controls, secure report delivery and documented consent address operational and confidentiality risks without assuming that accreditation is already obtained.

Demand for accessible local diagnostics supports a laboratory offering dependable turnaround and traceable results. Clinics and employers may provide recurring work, while walk-in patients diversify collections. Management will build referral relationships around quality and service consistency, with specialised panels introduced only where equipment capability and expected throughput justify the reagent and quality-control costs. These strengths are balanced by the need to manage utilisation, cost discipline and collection performance. The projection should be stress-tested for lower sales, higher input prices and a longer collection cycle, with repayment reviewed against the resulting cash accruals rather than solely against the base-case margin.

Repayment capacity is assessed from operating cash accruals after the scheduled interest charge and with principal obligations considered in the debt-service schedule. Accounting profit alone does not establish available bank cash: inventory growth, receivable delays and capital expenditure can absorb accruals. Management should maintain a rolling cash forecast and reserve funds for instalments before discretionary expenditure or distributions. Insurance, supplier continuity arrangements and timely statutory renewals should be reviewed annually. The bank should receive prompt explanations for material deviations from the sanctioned operating assumptions.

Financial Analysis

For the first reporting year, FY 2026-27, the computed schedules show sales of Rs. 310.00 lakh and net profit of Rs. 41.61 lakh. The first-year current ratio is 1.70 times and the arithmetic average of the annual DSCR values in the repayment schedule is 2.90 times. Final-year sales are Rs. 421.75 lakh with net profit of Rs. 76.40 lakh; these highlights reproduce the report's calculations rather than a separate earnings estimate.

The funding schedule provides a total outlay of Rs. 232.40 lakh, promoter contribution of Rs. 101.20 lakh, term finance of Rs. 118.80 lakh and cash credit of Rs. 12.40 lakh. The term facility is modelled at 9.5% over five years with a six-month moratorium; working-capital interest is modelled at 10%. Security documentation and final repayment terms remain subject to the bank's appraisal and sanction.

Repayment capacity is assessed from operating cash accruals after the scheduled interest charge and with principal obligations considered in the debt-service schedule. Accounting profit alone does not establish available bank cash: inventory growth, receivable delays and capital expenditure can absorb accruals. Management should maintain a rolling cash forecast and reserve funds for instalments before discretionary expenditure or distributions. Monthly management review should compare orders, realised prices, direct costs and collections with the financial schedules. Stock and debtor statements must reconcile with the books before

submission to the bank. Any adverse movement in margin or overdue accounts should lead to a revised cash-flow forecast and corrective action before additional credit commitments are accepted.

Conclusion and Recommendations

FINXORA DIAGNOSTICS LLP's proposal connects pathology laboratory service activity with an identified operating plan, a defined promoter contribution and scheduled bank finance. Demand for accessible local diagnostics supports a laboratory offering dependable turnaround and traceable results. Clinics and employers may provide recurring work, while walk-in patients diversify collections. Management will build referral relationships around quality and service consistency, with specialised panels introduced only where equipment capability and expected throughput justify the reagent and quality-control costs. The computed liquidity and debt-service indicators support consideration of the proposal under the stated assumptions; they should be read with the detailed operating, balance-sheet and repayment schedules.

A slower referral build-up, equipment failure and errors in sample handling can affect both revenue and reputation. Phased marketing, preventive maintenance and approved referral-laboratory backup reduce interruption risk. Staff competency checks, internal controls, secure report delivery and documented consent address operational and confidentiality risks without assuming that accreditation is already obtained. Prior to sanction or renewal, the bank should examine promoter contribution, premises arrangements, equipment quotations, customer demand, statutory permissions and the proposed security. Disbursement should follow documented end use and completion of the agreed conditions.

Management should provide periodic stock, debtor and operating statements and discuss material deviations with the lender. Expansion should remain within demonstrated operational capacity and available working capital. This assessment is conditional on execution of the operating plan and timely collections; it does not constitute a guarantee of sanction, future profit or uninterrupted debt service.

This is a sample report prepared with Finxora; the business and its figures are illustrative.

SALES & PURCHASE BREAKDOWN

Sales

Sales - Monthly Bifurcation (Quantity x Rate)

Particulars	Unit	Quantity	Rate	Monthly Amount
Sales of Goods	—	—	—	25,83,333.33
Routine pathology panels	test	3,100.00	500.00	15,50,000.00
Specialised diagnostic panels	test	861.11	1,200.00	10,33,333.33
Total Sales	—	—	—	51,66,666.66

Sales - Yearly Projection (Year 1)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Sales of Goods	—	—	12	—	25,83,333.33	3,10,00,000.00
Routine pathology panels	test	3,100.00	12	37,200.00	15,50,000.00	1,86,00,000.00
Specialised diagnostic panels	test	861.11	12	10,333.33	10,33,333.33	1,23,99,999.96
Total Sales	—	—	12	—	51,66,666.66	6,19,99,999.96

Sales - Yearly Projection (Year 2)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Sales of Goods	—	—	12	—	27,90,000.00	3,34,80,000.00
Routine pathology panels	test	3,875.00	12	46,500.00	19,37,500.00	2,32,50,000.00
Specialised diagnostic panels	test	1,076.39	12	12,916.67	12,91,666.66	1,54,99,999.95
Total Sales	—	—	12	—	60,19,166.66	7,22,29,999.95

Sales - Yearly Projection (Year 3)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Sales of Goods	—	—	12	—	30,13,200.00	3,61,58,400.00
Routine pathology panels	test	4,843.75	12	58,125.00	24,21,875.00	2,90,62,500.00
Specialised diagnostic panels	test	1,345.49	12	16,145.83	16,14,583.33	1,93,74,999.94
Total Sales	—	—	12	—	70,49,658.33	8,45,95,899.94

Sales - Yearly Projection (Year 4)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Sales of Goods	—	—	12	—	32,54,256.00	3,90,51,072.00
Routine pathology panels	test	6,054.69	12	72,656.25	30,27,343.75	3,63,28,125.00
Specialised diagnostic panels	test	1,681.86	12	20,182.29	20,18,229.16	2,42,18,749.92
Total Sales	—	—	12	—	82,99,828.91	9,95,97,946.92

Sales - Yearly Projection (Year 5)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Sales of Goods	—	—	12	—	35,14,596.48	4,21,75,157.76
Routine pathology panels	test	7,568.36	12	90,820.31	37,84,179.69	4,54,10,156.25
Specialised diagnostic panels	test	2,102.32	12	25,227.86	25,22,786.45	3,02,73,437.40
Total Sales	—	—	12	—	98,21,562.62	11,78,58,751.41

Purchase

Purchase - Monthly Bifurcation (Quantity x Rate)

Particulars	Unit	Quantity	Rate	Monthly Amount
Purchase of Goods	—	—	—	8,05,787.67
Routine pathology panels reagents and outsourced work (for Routine pathology panels @ 100% recovery)	test	3,100.00	155.96	4,83,472.60
Specialised diagnostic panels reagents and outsourced work (for Specialised diagnostic panels @ 100% recovery)	test	861.11	374.30	3,22,315.07
Total Purchase	—	—	—	16,11,575.34

Purchase - Yearly Projection (Year 1)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Purchase of Goods	—	—	12	—	8,05,787.67	96,69,452.05
Routine pathology panels reagents and outsourced work	test	3,100.00	12	37,200.00	4,83,472.60	58,01,671.20
Specialised diagnostic panels reagents and outsourced work	test	861.11	12	10,333.33	3,22,315.07	38,67,780.84
Total Purchase	—	—	12	—	16,11,575.34	1,93,38,904.09

Purchase - Yearly Projection (Year 2)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Purchase of Goods	—	—	12	—	8,13,629.68	97,63,556.16
Routine pathology panels reagents and outsourced work	test	3,565.00	12	42,780.00	5,55,993.49	66,71,921.88
Specialised diagnostic panels reagents and outsourced work	test	990.28	12	11,883.33	3,70,662.33	44,47,947.97
Total Purchase	—	—	12	—	17,40,285.50	2,08,83,426.01

Purchase - Yearly Projection (Year 3)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Purchase of Goods	—	—	12	—	8,78,720.06	1,05,44,640.66
Routine pathology panels reagents and outsourced work	test	4,099.75	12	49,197.00	6,39,392.51	76,72,710.16
Specialised diagnostic panels reagents and outsourced	test	1,138.82	12	13,665.83	4,26,261.68	51,15,140.16

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
work						
Total Purchase	—	—	12	—	19,44,374.25	2,33,32,490.98

Purchase - Yearly Projection (Year 4)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Purchase of Goods	—	—	12	—	9,49,017.66	1,13,88,211.91
Routine pathology panels reagents and outsourced work	test	4,714.71	12	56,576.55	7,35,301.39	88,23,616.69
Specialised diagnostic panels reagents and outsourced work	test	1,309.64	12	15,715.71	4,90,200.93	58,82,411.19
Total Purchase	—	—	12	—	21,74,519.98	2,60,94,239.78

Purchase - Yearly Projection (Year 5)

Particulars	Unit	Monthly Qty	Months	Annual Qty	Monthly Amount	Yearly Amount
Purchase of Goods	—	—	12	—	10,24,939.07	1,22,99,268.86
Routine pathology panels reagents and outsourced work	test	5,421.92	12	65,063.03	8,45,596.60	1,01,47,159.19
Specialised diagnostic panels reagents and outsourced work	test	1,506.09	12	18,073.06	5,63,731.07	67,64,772.86
Total Purchase	—	—	12	—	24,34,266.74	2,92,11,200.91

Revenue & expenses

Particulars	Monthly Amount
Sales & Revenue	
Routine pathology panels	15,50,000.00
Specialised diagnostic panels	10,33,333.33
Total Sales Revenue	25,83,333.33
Purchases	
Routine pathology panels reagents and outsourced work	4,83,472.60
Specialised diagnostic panels reagents and outsourced work	3,22,315.07
Total Purchases	8,05,787.67
Administrative Expenses	
Salaries & Wages	1,16,250.00
Rent	46,500.00
Utilities (Electricity, Water, etc.)	31,000.00
Office Supplies & Stationery	11,625.00
Communication (Phone, Internet)	11,625.00
Travel & Conveyance	23,250.00
Professional Fees	15,500.00
Insurance	15,500.00
Repairs & Maintenance	23,250.00
Bank Charges	7,750.00
Total Administrative Expenses	3,02,250.00
Selling & Distribution Expenses	
Advertising & Marketing	38,750.00
Freight & Transportation	38,750.00
Other Direct Expenses	7,750.00
Power & Fuel	77,500.00
Technical and field staff costs	4,90,833.33
Other direct service costs	51,666.67
Total Selling & Distribution Expenses	7,05,250.00
Closing Stock	
Closing Stock Value (yearly)	6,79,452.05

Project Cost Breakdown

Item	Amount
Land	22,00,000.00
Building	55,00,000.00
Plant & machinery / equipment	99,00,000.00
Furniture & fixtures	11,00,000.00
Vehicles	33,00,000.00
Working capital	12,40,000.00
Total Project Cost	2,32,40,000.00

Means of Finance

Item	Amount
Term Loan	1,18,80,000.00
Working Capital Loan	12,40,000.00
Total loan	1,31,20,000.00
Promoters contribution on term loan	1,01,20,000.00
Total	2,32,40,000.00

Profit & Loss Account

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
SALES					
Pathology laboratory service income	3,10,00,000.00	3,34,80,000.00	3,61,58,400.00	3,90,51,072.00	4,21,75,157.76
Total Sales	3,10,00,000.00	3,34,80,000.00	3,61,58,400.00	3,90,51,072.00	4,21,75,157.76
Closing Stock	6,79,452.05	7,33,808.22	7,92,512.88	8,55,913.91	9,24,387.02
Opening Stock	0.00	6,79,452.05	7,33,808.22	7,92,512.88	8,55,913.91
PURCHASES					
Consumables and outsourced service costs	96,69,452.05	97,63,556.16	1,05,44,640.66	1,13,88,211.91	1,22,99,268.86
Total Purchases	96,69,452.05	97,63,556.16	1,05,44,640.66	1,13,88,211.91	1,22,99,268.86
DIRECT EXPENSES					
Advertising & Marketing	4,65,000.00	5,02,200.00	5,42,376.00	5,85,766.08	6,32,627.37
Freight & Transportation	4,65,000.00	5,02,200.00	5,42,376.00	5,85,766.08	6,32,627.37
Other Direct Expenses	93,000.00	1,00,440.00	1,08,475.20	1,17,153.22	1,26,525.47
Power & Fuel	9,30,000.00	10,04,400.00	10,84,752.00	11,71,532.16	12,65,254.73
Technical and field staff costs	58,90,000.00	63,61,200.00	68,70,096.00	74,19,703.68	80,13,279.97
Other direct service costs	6,20,000.00	6,69,600.00	7,23,168.00	7,81,021.44	8,43,503.16
Total Direct Expenses	84,63,000.00	91,40,040.00	98,71,243.20	1,06,60,942.66	1,15,13,818.07
GROSS PROFIT	1,35,47,000.00	1,46,30,760.01	1,58,01,220.80	1,70,65,318.46	1,84,30,543.94
INDIRECT EXPENSES					
Salaries & Wages	13,95,000.00	15,06,600.00	16,27,128.00	17,57,298.24	18,97,882.10
Rent	5,58,000.00	6,02,640.00	6,50,851.20	7,02,919.30	7,59,152.84
Utilities (Electricity, Water, etc.)	3,72,000.00	4,01,760.00	4,33,900.80	4,68,612.86	5,06,101.89
Office Supplies & Stationery	1,39,500.00	1,50,660.00	1,62,712.80	1,75,729.82	1,89,788.21
Communication (Phone, Internet)	1,39,500.00	1,50,660.00	1,62,712.80	1,75,729.82	1,89,788.21
Travel & Conveyance	2,79,000.00	3,01,320.00	3,25,425.60	3,51,459.65	3,79,576.42
Professional Fees	1,86,000.00	2,00,880.00	2,16,950.40	2,34,306.43	2,53,050.95
Insurance	1,86,000.00	2,00,880.00	2,16,950.40	2,34,306.43	2,53,050.95
Repairs & Maintenance	2,79,000.00	3,01,320.00	3,25,425.60	3,51,459.65	3,79,576.42
Bank Charges	93,000.00	1,00,440.00	1,08,475.20	1,17,153.22	1,26,525.47
Depreciation	26,40,000.00	22,77,000.00	19,65,150.00	16,97,107.51	14,66,598.37
Interest on WCL	1,24,000.00	1,24,000.00	1,24,000.00	1,24,000.00	1,24,000.00
Interest on TL	11,07,337.42	9,25,927.08	6,94,805.58	4,40,745.84	1,61,471.27
Total Indirect Expenses	74,98,337.42	72,44,087.08	70,14,488.38	68,30,828.77	66,86,563.10
EBDIT (PBDIT)	99,20,000.00	1,07,13,600.01	1,15,70,688.00	1,24,96,343.04	1,34,96,050.48
Profit Before Tax	60,48,662.58	73,86,672.93	87,86,732.42	1,02,34,489.69	1,17,43,980.84
Provision for Income Tax	18,87,182.72	23,04,641.95	27,41,460.51	33,63,869.28	41,03,816.66
NET PROFIT	41,61,479.86	50,82,030.98	60,45,271.91	68,70,620.41	76,40,164.18

Cash Flow Statement

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Cash Inflow					
Capital	1,01,20,000.00	0.00	0.00	0.00	0.00
Subsidy	0.00	0.00	0.00	0.00	0.00
Termloan	1,18,80,000.00	0.00	0.00	0.00	0.00
Working Capital Loan	12,40,000.00	0.00	0.00	0.00	0.00
Increase in Current Liabilities	25,02,936.14	4,66,719.51	4,90,019.65	6,79,865.96	8,02,001.14
Increase in Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Increase in Non-Term Liabilities	0.00	0.00	0.00	0.00	0.00
Increase in Other Term Liabilities	0.00	0.00	0.00	0.00	0.00
Decrease in Current Assets	0.00	0.00	0.00	0.00	0.00
Decrease in Non-Current Assets	0.00	0.00	0.00	0.00	0.00
Decrease in Investments	0.00	0.00	0.00	0.00	0.00
Profit before tax with interest	72,80,000.00	84,36,600.01	96,05,538.00	1,07,99,235.53	1,20,29,452.11
Depreciation	26,40,000.00	22,77,000.00	19,65,150.00	16,97,107.51	14,66,598.37
Total Cash Inflow	3,56,62,936.14	1,11,80,319.52	1,20,60,707.65	1,31,76,209.00	1,42,98,051.62
Cash Outflow					
Fixed Assets	2,20,00,000.00	0.00	0.00	0.00	0.00
Increase in Current Assets	40,76,712.32	3,26,137.00	3,52,227.94	3,80,406.18	4,10,838.68
Increase in Non-Current Assets	0.00	0.00	0.00	0.00	0.00
Increase in Investments	0.00	0.00	0.00	0.00	0.00
Interest on TL	11,07,337.42	9,25,927.08	6,94,805.58	4,40,745.84	1,61,471.27
Interest on WCL	1,24,000.00	1,24,000.00	1,24,000.00	1,24,000.00	1,24,000.00
Decrease in Term loan	8,99,997.52	23,10,445.71	25,39,751.87	27,91,816.11	30,68,897.11
Decrease in Working Capital Loan	0.00	0.00	0.00	0.00	0.00
Drawing	14,56,517.95	17,78,710.84	21,15,845.17	24,04,717.14	26,74,057.46
Provision for Income Tax	18,87,182.72	23,04,641.95	27,41,460.51	33,63,869.28	41,03,816.66
Decrease in Current Liabilities	0.00	0.00	0.00	0.00	0.00
Decrease in Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Decrease in Other Term Liabilities	0.00	0.00	0.00	0.00	0.00
Decrease in Non-Term Liabilities	0.00	0.00	0.00	0.00	0.00
Total Cash Outflow	3,15,51,747.93	77,69,862.58	85,68,091.07	95,05,554.55	1,05,43,081.18
Opening balance	0.00	41,11,188.20	75,21,645.14	1,10,14,261.72	1,46,84,916.16
Net Cashflow	41,11,188.20	34,10,456.94	34,92,616.58	36,70,654.44	37,54,970.42
Closing balance	41,11,188.20	75,21,645.14	1,10,14,261.72	1,46,84,916.16	1,84,39,886.58

Balance Sheet

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
CAPITAL ACCOUNT					
Capital	1,01,20,000.00	1,28,24,961.91	1,61,28,282.05	2,00,57,708.79	2,45,23,612.06
Profit & Loss A/c	41,61,479.86	50,82,030.98	60,45,271.91	68,70,620.41	76,40,164.18
Drawings (Withdrawal)	14,56,517.95	17,78,710.84	21,15,845.17	24,04,717.14	26,74,057.46
NET WORTH	1,28,24,961.91	1,61,28,282.05	2,00,57,708.79	2,45,23,612.06	2,94,89,718.78
LOAN LIABILITIES					
Working Capital Loan	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
TOTAL LOAN LIABILITIES	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00	12,40,000.00
CURRENT LIABILITIES					
Sundry Creditor (Trade)	6,15,753.42	6,65,013.70	7,18,214.79	7,75,671.98	8,37,725.74
Provision for Income Tax	18,87,182.72	23,04,641.95	27,41,460.51	33,63,869.28	41,03,816.66
Current Portion of Term Loan	23,10,445.71	25,39,751.87	27,91,816.11	30,68,897.11	0.00
TOTAL CURRENT LIABILITIES	48,13,381.85	55,09,407.52	62,51,491.41	72,08,438.37	49,41,542.40
TERM LIABILITIES					
Term Loan	86,69,556.76	61,29,804.89	33,37,988.79	2,69,091.68	2,69,091.68
TOTAL TERM LIABILITIES	86,69,556.76	61,29,804.89	33,37,988.79	2,69,091.68	2,69,091.68
NON CURRENT LIABILITIES					
TOTAL EQUITY + LIABILITY	2,75,47,900.52	2,90,07,494.46	3,08,87,188.99	3,32,41,142.11	3,59,40,352.86
FIXED ASSETS					
Gross Block	2,20,00,000.00	1,93,60,000.00	1,70,83,000.00	1,51,17,850.00	1,34,20,742.51
Depreciation to date	26,40,000.00	22,77,000.00	19,65,150.00	16,97,107.51	14,66,598.37
NET BLOCK	1,93,60,000.00	1,70,83,000.00	1,51,17,850.00	1,34,20,742.49	1,19,54,144.14
CURRENT ASSETS					
Cash & Cash Equivalents	41,11,188.20	75,21,645.14	1,10,14,261.72	1,46,84,916.16	1,84,39,886.58
Inventory	6,79,452.05	7,33,808.22	7,92,512.88	8,55,913.91	9,24,387.02
Sundry Debtors	33,97,260.27	36,69,041.10	39,62,564.38	42,79,569.53	46,21,935.10
TOTAL CURRENT ASSETS	81,87,900.52	1,19,24,494.46	1,57,69,338.98	1,98,20,399.60	2,39,86,208.70
NON CURRENT ASSETS					
TOTAL ASSETS	2,75,47,900.52	2,90,07,494.46	3,08,87,188.98	3,32,41,142.09	3,59,40,352.84
Difference	0.00	0.00	0.01	0.02	0.02

Depreciation

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Land	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00
During the Year (>= 180 days)					
During the Year (< 180 days)					
Total During the Year	0.00	0.00	0.00	0.00	0.00
Total	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00
Less Depreciation	0.00	0.00	0.00	0.00	0.00
Adjust (Dep) (Add/Less)					
Written down value	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00	22,00,000.00
Building	55,00,000.00	49,50,000.00	44,55,000.00	40,09,500.00	36,08,550.00
During the Year (>= 180 days)					
During the Year (< 180 days)					
Total During the Year	0.00	0.00	0.00	0.00	0.00
Total	55,00,000.00	49,50,000.00	44,55,000.00	40,09,500.00	36,08,550.00
Less Depreciation	5,50,000.00	4,95,000.00	4,45,500.00	4,00,950.00	3,60,855.00
Adjust (Dep) (Add/Less)					
Written down value	49,50,000.00	44,55,000.00	40,09,500.00	36,08,550.00	32,47,695.00
Furniture & Fixtures	11,00,000.00	9,90,000.00	8,91,000.00	8,01,900.00	7,21,710.00
During the Year (>= 180 days)					
During the Year (< 180 days)					
Total During the Year	0.00	0.00	0.00	0.00	0.00
Total	11,00,000.00	9,90,000.00	8,91,000.00	8,01,900.00	7,21,710.00
Less Depreciation	1,10,000.00	99,000.00	89,100.00	80,190.00	72,171.00
Adjust (Dep) (Add/Less)					
Written down value	9,90,000.00	8,91,000.00	8,01,900.00	7,21,710.00	6,49,539.00
Plant & Machinery	99,00,000.00	84,15,000.00	71,52,750.00	60,79,837.50	51,67,861.88
During the Year (>= 180 days)					
During the Year (< 180 days)					
Total During the Year	0.00	0.00	0.00	0.00	0.00
Total	99,00,000.00	84,15,000.00	71,52,750.00	60,79,837.50	51,67,861.88
Less Depreciation	14,85,000.00	12,62,250.00	10,72,912.50	9,11,975.63	7,75,179.28
Adjust (Dep) (Add/Less)					
Written down value	84,15,000.00	71,52,750.00	60,79,837.50	51,67,861.88	43,92,682.60
Vehicles	33,00,000.00	28,05,000.00	23,84,250.00	20,26,612.50	17,22,620.63
During the Year (>= 180 days)					
During the Year (< 180 days)					
Total During the Year	0.00	0.00	0.00	0.00	0.00

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Total	33,00,000.00	28,05,000.00	23,84,250.00	20,26,612.50	17,22,620.63
Less Depreciation	4,95,000.00	4,20,750.00	3,57,637.50	3,03,991.88	2,58,393.09
Adjust (Dep) (Add/Less)					
Written down value	28,05,000.00	23,84,250.00	20,26,612.50	17,22,620.63	14,64,227.54
Opening	2,20,00,000.00	1,93,60,000.00	1,70,83,000.00	1,51,17,850.00	1,34,20,742.51
Total During the Year	0.00	0.00	0.00	0.00	0.00
Gross Block	2,20,00,000.00	1,93,60,000.00	1,70,83,000.00	1,51,17,850.00	1,34,20,742.51
Total less depreciation	26,40,000.00	22,77,000.00	19,65,150.00	16,97,107.51	14,66,598.37
Total Adjust (Dep) (Add/Less)	0.00	0.00	0.00	0.00	0.00
Total written down value	1,93,60,000.00	1,70,83,000.00	1,51,17,850.00	1,34,20,742.51	1,19,54,144.14

Breakeven Point

Particulars	2026-2027 (projected)	2027-2028 (projected)	2028-2029 (projected)	2029-2030 (projected)	2030-2031 (projected)
Sales Analysis					
Total Sales Revenue	3,10,00,000.00	3,34,80,000.00	3,61,58,400.00	3,90,51,072.00	4,21,75,157.76
Cost Analysis					
Fixed Costs	74,98,337.42	72,44,087.08	70,14,488.38	68,30,828.77	66,86,563.10
Variable Costs	1,74,53,000.00	1,88,49,239.99	2,03,57,179.20	2,19,85,753.54	2,37,44,613.82
Total Costs	2,49,51,337.42	2,60,93,327.07	2,73,71,667.58	2,88,16,582.31	3,04,31,176.92
Contribution Analysis					
Contribution Margin	1,35,47,000.00	1,46,30,760.01	1,58,01,220.80	1,70,65,318.46	1,84,30,543.94
Contribution Ratio (%)	43.70	43.70	43.70	43.70	43.70
Break-Even Analysis					
Break-even Value	1,71,58,666.86	1,65,76,858.30	1,60,51,460.82	1,56,31,187.12	1,53,01,059.73
Break-even Point (%)	55.35	49.51	44.39	40.03	36.28
Margin of Safety (Value)	1,38,41,333.14	1,69,03,141.70	2,01,06,939.18	2,34,19,884.88	2,68,74,098.03
Margin of Safety (%)	44.65	50.49	55.61	59.97	63.72

EMI Repayment Schedule

Month	Payment Date	Opening Bal.	EMI	Principal	Interest	Closing Bal.
1	01 Apr 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
2	01 May 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
3	01 Jun 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
4	01 Jul 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
5	01 Aug 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
6	01 Sept 2026	1,18,80,000.00	94,050.00	0.00	94,050.00	1,18,80,000.00
7	01 Oct 2026	1,18,80,000.00	2,71,221.99	1,77,171.99	94,050.00	1,17,02,828.01
8	01 Nov 2026	1,17,02,828.01	2,71,221.99	1,78,574.60	92,647.39	1,15,24,253.42
9	01 Dec 2026	1,15,24,253.42	2,71,221.99	1,79,988.31	91,233.67	1,13,44,265.11
10	01 Jan 2027	1,13,44,265.11	2,71,221.99	1,81,413.22	89,808.77	1,11,62,851.89
11	01 Feb 2027	1,11,62,851.89	2,71,221.99	1,82,849.41	88,372.58	1,09,80,002.48
12	01 Mar 2027	1,09,80,002.48	2,71,221.99	1,84,296.97	86,925.02	1,07,95,705.51
13	01 Apr 2027	1,07,95,705.51	2,71,221.99	1,85,755.98	85,466.00	1,06,09,949.53
14	01 May 2027	1,06,09,949.53	2,71,221.99	1,87,226.55	83,995.43	1,04,22,722.98
15	01 Jun 2027	1,04,22,722.98	2,71,221.99	1,88,708.76	82,513.22	1,02,34,014.22
16	01 Jul 2027	1,02,34,014.22	2,71,221.99	1,90,202.71	81,019.28	1,00,43,811.51
17	01 Aug 2027	1,00,43,811.51	2,71,221.99	1,91,708.48	79,513.51	98,52,103.03
18	01 Sept 2027	98,52,103.03	2,71,221.99	1,93,226.17	77,995.82	96,58,876.87
19	01 Oct 2027	96,58,876.87	2,71,221.99	1,94,755.88	76,466.11	94,64,120.99
20	01 Nov 2027	94,64,120.99	2,71,221.99	1,96,297.69	74,924.29	92,67,823.29
21	01 Dec 2027	92,67,823.29	2,71,221.99	1,97,851.72	73,370.27	90,69,971.58
22	01 Jan 2028	90,69,971.58	2,71,221.99	1,99,418.04	71,803.94	88,70,553.53
23	01 Feb 2028	88,70,553.53	2,71,221.99	2,00,996.77	70,225.22	86,69,556.76
24	01 Mar 2028	86,69,556.76	2,71,221.99	2,02,587.99	68,633.99	84,66,968.77
25	01 Apr 2028	84,66,968.77	2,71,221.99	2,04,191.82	67,030.17	82,62,776.95
26	01 May 2028	82,62,776.95	2,71,221.99	2,05,808.33	65,413.65	80,56,968.62
27	01 Jun 2028	80,56,968.62	2,71,221.99	2,07,437.65	63,784.33	78,49,530.97
28	01 Jul 2028	78,49,530.97	2,71,221.99	2,09,079.86	62,142.12	76,40,451.11
29	01 Aug 2028	76,40,451.11	2,71,221.99	2,10,735.08	60,486.90	74,29,716.02
30	01 Sept 2028	74,29,716.02	2,71,221.99	2,12,403.40	58,818.59	72,17,312.62
31	01 Oct 2028	72,17,312.62	2,71,221.99	2,14,084.93	57,137.06	70,03,227.70
32	01 Nov 2028	70,03,227.70	2,71,221.99	2,15,779.77	55,442.22	67,87,447.93
33	01 Dec 2028	67,87,447.93	2,71,221.99	2,17,488.02	53,733.96	65,69,959.91
34	01 Jan 2029	65,69,959.91	2,71,221.99	2,19,209.80	52,012.18	63,50,750.11
35	01 Feb 2029	63,50,750.11	2,71,221.99	2,20,945.21	50,276.77	61,29,804.89
36	01 Mar 2029	61,29,804.89	2,71,221.99	2,22,694.36	48,527.62	59,07,110.53

Month	Payment Date	Opening Bal.	EMI	Principal	Interest	Closing Bal.
37	01 Apr 2029	59,07,110.53	2,71,221.99	2,24,457.36	46,764.63	56,82,653.17
38	01 May 2029	56,82,653.17	2,71,221.99	2,26,234.31	44,987.67	54,56,418.86
39	01 Jun 2029	54,56,418.86	2,71,221.99	2,28,025.34	43,196.65	52,28,393.52
40	01 Jul 2029	52,28,393.52	2,71,221.99	2,29,830.54	41,391.45	49,98,562.98
41	01 Aug 2029	49,98,562.98	2,71,221.99	2,31,650.03	39,571.96	47,66,912.96
42	01 Sept 2029	47,66,912.96	2,71,221.99	2,33,483.92	37,738.06	45,33,429.03
43	01 Oct 2029	45,33,429.03	2,71,221.99	2,35,332.34	35,889.65	42,98,096.69
44	01 Nov 2029	42,98,096.69	2,71,221.99	2,37,195.39	34,026.60	40,60,901.31
45	01 Dec 2029	40,60,901.31	2,71,221.99	2,39,073.18	32,148.80	38,21,828.12
46	01 Jan 2030	38,21,828.12	2,71,221.99	2,40,965.85	30,256.14	35,80,862.28
47	01 Feb 2030	35,80,862.28	2,71,221.99	2,42,873.49	28,348.49	33,37,988.79
48	01 Mar 2030	33,37,988.79	2,71,221.99	2,44,796.24	26,425.74	30,93,192.55
49	01 Apr 2030	30,93,192.55	2,71,221.99	2,46,734.21	24,487.77	28,46,458.34
50	01 May 2030	28,46,458.34	2,71,221.99	2,48,687.52	22,534.46	25,97,770.81
51	01 Jun 2030	25,97,770.81	2,71,221.99	2,50,656.30	20,565.69	23,47,114.51
52	01 Jul 2030	23,47,114.51	2,71,221.99	2,52,640.66	18,581.32	20,94,473.85
53	01 Aug 2030	20,94,473.85	2,71,221.99	2,54,640.73	16,581.25	18,39,833.12
54	01 Sept 2030	18,39,833.12	2,71,221.99	2,56,656.64	14,565.35	15,83,176.48
55	01 Oct 2030	15,83,176.48	2,71,221.99	2,58,688.50	12,533.48	13,24,487.97
56	01 Nov 2030	13,24,487.97	2,71,221.99	2,60,736.46	10,485.53	10,63,751.52
57	01 Dec 2030	10,63,751.52	2,71,221.99	2,62,800.62	8,421.37	8,00,950.90
58	01 Jan 2031	8,00,950.90	2,71,221.99	2,64,881.12	6,340.86	5,36,069.78
59	01 Feb 2031	5,36,069.78	2,71,221.99	2,66,978.10	4,243.89	2,69,091.68
60	01 Mar 2031	2,69,091.68	2,71,221.99	2,69,091.68	2,130.31	0.00

EXPLANATIONS & CONCLUSION

Assumptions

The entire projection is based on the assumption that the sales for 5 years will be as follows:

31/03/2027	31/03/2028	31/03/2029	31/03/2030	31/03/2031
3,10,00,000.00	3,34,80,000.00	3,61,58,400.00	3,90,51,072.00	4,21,75,157.76

Revenue From Sales : 3,10,00,000.00

Also the total expense for the firm during the projection years will be as follows:

31/03/2027	31/03/2028	31/03/2029	31/03/2030	31/03/2031
1,59,61,337.42	1,63,84,127.08	1,68,85,731.58	1,74,91,771.43	1,82,00,381.17

Loan Assumptions:

- Term Loan: Principal 1,18,80,000.00, Interest 9.5%, Duration 5 years
- Working Capital Loan: Principal 12,40,000.00, Interest 10%

The depreciation is as follows:

Particulars	Rate
Building	10%
Furniture & Fixtures	10%
Plant & Machinery	15%
Vehicles	15%

- Cost of Machinery is based on direct purchase from the market on deepest study
- Value of raw materials & utility charges as per the current market conditions
- All other assumptions are calculated based on the basis of experience of the promoter and deep study on the working of similar model

Conclusion

When we take a close look at the Debt Service Coverage Ratio (DSCR), the avg: DSCR is 2.90 : 1, which is at a higher proposition and proposes a stable venture.